Browse the evidence

Depression is uniquely and significantly associated with increased GLP-1RA utilization in women, suggesting a complex interplay between mental health comorbidities and medication access.

For women, having a diagnosis of depression is linked to a higher likelihood of being prescribed GLP-1RAs. This may reflect targeted prescribing or the complex relationship between mental health and weight management. It highlights the need for sex-sensitive screening and holistic care that addresses both metabolic and psychiatric health.

Maxillomandibular advancement (MMA) surgery achieves the largest and most durable reductions in OSA severity, with efficacy comparable to CPAP.

If you have severe sleep apnea and cannot use CPAP, ask about Maxillomandibular Advancement (MMA) surgery. It is a major surgery but can provide a permanent, CPAP-level reduction in apnea events for the right candidate.

There are confirmed cases of falsified GLP-1 receptor agonists in Brazil, indicating supply chain vulnerabilities.

Counterfeit GLP-1 drugs have been confirmed in Brazil. Patients should obtain medications through regulated channels to avoid falsified products.

The presence of anti-drug antibodies (ADAs) to GLP-1 receptor agonists does not necessarily neutralize their clinical efficacy, although it may increase the risk of hypersensitivity reactions.

If you develop antibodies to your GLP-1 medication, it does not automatically mean it has stopped working for weight loss. However, you may experience more injection site reactions. Discuss these symptoms with your doctor; they may not need to stop the drug unless side effects are severe.

Intensive lifestyle interventions (diet and exercise) alone are insufficient to prevent significant weight regain after discontinuation of incretin-based therapy, although they may modestly attenuate the rebound.

Even if you commit to intense diet and exercise after stopping your weight loss medication, you will likely regain a significant amount of weight. Lifestyle changes are important for your health, but they are not a substitute for the medication's hormonal effects in preventing regain.

GLP-1 and GIP receptor agonists improve hepatic outcomes in metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), including resolution of MASH and improvement in fibrosis.

GLP-1 therapies can significantly improve liver health in patients with MASH, including resolving the disease and improving fibrosis in many cases. This benefit is partly due to weight loss but also involves direct effects on liver tissue. Early treatment is crucial, as benefits are not seen in advanced cirrhosis. Patients with fatty liver should discuss these options with their doctor.

GLP-1 receptor agonists (GLP-1RAs) cause frequent, dose-dependent gastrointestinal adverse effects (nausea, vomiting, diarrhea, constipation, reflux) that typically diminish over time but are a major cause of treatment discontinuation.

If you start a GLP-1 medication, expect digestive issues like nausea or diarrhea in the first few months. These symptoms are very common (affecting half to 60% of users) and are usually dose-dependent. The good news is that they typically get better over time. Starting with a lower dose and increasing slowly can help manage this.

GLP-1RAs are associated with an increased risk of hypoglycemia, particularly when combined with insulin or sulfonylureas, although the risk remains lower than with those agents alone.

If you take a GLP-1 medication along with insulin or sulfonylureas, your risk of low blood sugar (hypoglycemia) increases. However, this risk is still lower than if you were taking insulin or sulfonylureas alone. Monitor your blood sugar as advised by your doctor.

Sarcopenia is driven by anabolic resistance, mitochondrial dysfunction, and chronic inflammation, which decouple muscle mass from muscle function.

Understanding that muscle mass and function are different helps explain why you might look stronger but still feel weak. Treating the underlying inflammation and mitochondrial health is as important as building size.

Metabolic surgery (RYGB/VSG) improves glycemic control and induces T2DM remission through weight-loss-independent mechanisms, specifically by altering bile acid metabolism (FXR/TGR5 pathways), increasing incretin hormones (GLP-1/PYY), and modulating the gut microbiome, in addition to caloric restriction.

Metabolic surgery works by changing how your body processes food signals (hormones and bile acids), not just by making you eat less. This reset can lead to diabetes remission even before significant weight loss occurs, suggesting that the procedure alters the underlying biology of insulin resistance.

Metabolic surgery increases circulating levels of bile acids (BAs), which activate FXR and TGR5 receptors to suppress gluconeogenesis, improve insulin resistance, and stimulate GLP-1 secretion, thereby improving glucose homeostasis.

Surgery changes bile acid flow and concentration, which acts as a signaling molecule to tell the liver to stop producing excess sugar and to stimulate hormones that help insulin work better.

DPP-4 inhibitors (sitagliptin, saxagliptin, vildagliptin, linagliptin, alogliptin) are cardiovascularly safe (neutral effect on MACE) but do not significantly reduce cardiovascular events or mortality compared to placebo.

DPP-4 inhibitors (like sitagliptin) are safe for your heart and do not increase the risk of heart attacks or strokes, but they also do not reduce these risks. They are a good option for blood sugar control if you cannot tolerate other drugs, but if you have existing heart disease, doctors usually prefer SGLT-2 inhibitors or GLP-1 agonists because those have proven heart benefits.

A 6-month produce prescription program providing $60/month in vouchers for fruit and vegetables does not significantly improve glycemic control (HbA1c), blood pressure, or BMI in patients with diabetes compared to usual care.

For patients with diabetes, simply receiving vouchers for fruit and vegetables is not enough to lower blood sugar. To see health benefits, programs must ensure the voucher amount is sufficient for the patient's household size and include robust, ongoing nutritional education. Without these supports, financial incentives alone may fail to improve clinical outcomes.

Standard diagnostic biomarkers (BNP/NT-proBNP) are less reliable in obese patients with HF due to lower circulating levels caused by increased clearance by adipose tissue, requiring lower cut-off values for diagnosis.

If you are obese and have heart failure symptoms, standard blood tests for heart failure (BNP/NT-proBNP) might show lower levels than expected, even if you have the condition. Doctors should use lower thresholds to diagnose you. Do not assume a 'normal' result means you don't have heart failure if you have symptoms.

Novel antidiabetic agents, specifically SGLT-2 inhibitors, DPP-4 inhibitors, and GLP-1 receptor agonists, exert significant anti-inflammatory effects in the cardiovascular and renal systems, contributing to improved cardiorenal outcomes in type 2 diabetes.

If you have Type 2 Diabetes, ask your doctor about newer medications like SGLT-2 inhibitors or GLP-1 agonists. These drugs do more than just lower blood sugar; they actively reduce inflammation in your blood vessels and kidneys, which helps prevent heart attacks, strokes, and kidney failure. This benefit is independent of how well they control your glucose levels.

GLP-1 receptor agonists reduce cardiovascular inflammation by activating AMPK and CAMKKβ signaling pathways, leading to the downregulation of pro-inflammatory genes and increased SIRT6 expression.

This technical mechanism explains why GLP-1 drugs protect blood vessels. By activating specific cellular 'switches' (AMPK and SIRT6), these drugs turn off inflammatory genes in the vessel walls, preventing plaque buildup and stiffness.

DPP-4 inhibitors reduce systemic inflammation by suppressing the secretion of IL-6 and IL-1β and inhibiting NF-κB nuclear translocation, leading to improved endothelial function and plaque stabilization.

DPP-4 inhibitors (like sitagliptin) help stabilize heart disease plaques by reducing the inflammatory signals (IL-6, IL-1β) that attract immune cells to artery walls. This reduces the risk of plaque rupture and heart attacks.

The 'Dual Intervention Point' (DIP) model proposes that physiological regulation is weak within a 'zone of indifference' (dynamic equilibrium) but becomes strong only when fatness crosses upper or lower intervention points.

Your body's regulatory 'alarm bells' (hunger/satiety signals) may be quiet when you are within a normal weight range (zone of indifference). Strong physiological corrections only happen when you move significantly outside this range (crossing intervention points).

The evolution of human fat storage levels is driven by a trade-off between starvation risk and predation risk, resulting in an optimum fatness that minimizes total mortality, not maximum fat storage.

Your body stores fat to balance survival needs (starvation) against survival costs (predation/mobility). This explains why we don't store maximum possible fat; there is an evolutionary optimum.

Metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with a 19% increased risk of incident atrial fibrillation (AF), with risk escalating as liver disease severity (fibrosis/MASH) increases.

If you have MASLD, you have a significantly higher risk of developing atrial fibrillation, even in early stages. Managing metabolic risk factors (weight, blood sugar, blood pressure) is not just about liver health but is a critical strategy for preventing heart rhythm disorders. Early detection and comprehensive management of MASLD are crucial to mitigate this dual burden.

Obesity and Obstructive Sleep Apnea (OSA) exacerbate the risk of AF in MASLD through hemodynamic changes, epicardial fat deposition, and sympathetic nervous system activation.

For MASLD patients, managing weight and treating sleep apnea are critical for preventing AF. These conditions add mechanical and inflammatory stress to the heart, which can be mitigated through lifestyle and medical interventions.

Basal glucose homeostasis is governed by insulin-independent mechanisms primarily regulated by the brain, whereas glucose tolerance is determined by the interaction between insulin secretion and insulin sensitivity.

Understanding that fasting blood sugar (basal state) and how your body handles meals (glucose tolerance) are controlled by different systems can explain why some treatments work for one but not the other. Fasting glucose is largely managed by brain-mediated, insulin-independent processes, while meal response relies on insulin. This suggests that therapies targeting the brain (like certain GLP-1 agonists) may help basal glucose even if they don't fully restore insulin sensitivity.

Aging is associated with impaired glucose tolerance due to reduced insulin sensitivity and failure of insulin secretion to compensate, without changes in basal glucose or insulin-independent glucose disposal.

As you age, your body's ability to handle sugar after meals (glucose tolerance) declines due to insulin resistance and insufficient insulin response, but your fasting blood sugar may remain normal. This highlights the importance of monitoring post-meal glucose in older adults.

Patients with higher comorbidity burdens (cardiovascular risk, respiratory, pain, mental health) and higher BMI are significantly more likely to receive high-intensity interventions (surgery/procedures) rather than lifestyle intervention, while anti-obesity medications (AOMs) are underutilized relative to guidelines.

If you have obesity and comorbidities like diabetes or heart disease, you are more likely to get surgery or procedures than medication or lifestyle programs, even if guidelines suggest medication first. This is because providers often wait for severe BMI or complications before escalating care. You should discuss all options, including AOMs, with your provider rather than waiting for surgery eligibility.